- In November 2022, Danaher announced a strategic partnership with Duke University to establish its first Danaher Beacon for Gene Therapy Innovation. This initiative focuses on investing in product innovation and advancing external R&D, with an emphasis on genomic medicine, precision diagnostics, next-generation biomanufacturing, human systems, and data sciences
- In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics, a Poland-based company specializing in innovative medical diagnostic and healthcare technologies. This acquisition expanded Bio-Rad's product portfolio and strengthened its global market presence
- In April 2021, Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. announced the completion of patient enrollment for the Follicular Lymphoma Primary Efficacy Population in the global Phase 2 TIDAL study. This milestone marks a key advancement in their efforts to evaluate new therapeutic options for follicular lymphoma treatment
- In February 2021, Bristol Myers Squibb received FDA approval for its CAR-T cell therapy, Breyanzi, aimed at treating large B-cell lymphoma. This therapy is intended for patients who have relapsed or not responded to two prior types of systemic treatments, offering new hope for difficult-to-treat cases
- In December 2020, AstraZeneca announced that its cancer drug Calquence showed positive results in treating mantle cell lymphoma patients during its Phase 2 clinical trial. The success of the trial highlighted the drug's potential in providing a new treatment option for this rare and aggressive cancer
- In June 2020, Kyowa Kirin introduced their drug POTELIGO in Germany for the treatment of rare cancers such as mycosis fungoides and Sézary syndrome in adult patients. The drug's commercial availability aims to address the needs of patients with these difficult-to-treat skin cancers
Frequently Asked Questions
The market is segmented based on Global Non-Hodgkin Lymphoma Diagnostics Market Segmentation By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker, Genetic Test, Cytogenetics, Lumbar Puncture, Blood Test, Cytochemistry, and Others), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) – Industry Trends and Forecast to 2031
.
The Global Non Hodgkin Lymphoma Diagnostics Market size was valued at USD 11.38 USD Billion in 2023.
The Global Non Hodgkin Lymphoma Diagnostics Market is projected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
